Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Recurrence 1Neoplasms 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1

Interventions

Docetaxel 8pembrolizumab 7Pemetrexed 5Carboplatin 5Erlotinib Hydrochloride 4toripalimab 3rociletinib 3fludarabine 3Radiosurgery 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Gemcitabine 3Etoposide 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3lorlatinib 2atezolizumab 2Vinorelbine 2Topotecan 2Radiotherapy 2Platinum 2Itraconazole 2Irinotecan 2Interleukin-2 2Cetuximab 2Albumin-Bound Paclitaxel 2vinflunine 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × STA 9090 × Thoracic × Clear all
NCT01173523 2019-04-16

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
25 enrolled 8 charts
Thoracic

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡